KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Current Assets (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Current Assets for 6 consecutive years, with $812.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Assets rose 13.8% year-over-year to $812.8 million, compared with a TTM value of $812.8 million through Dec 2025, up 13.8%, and an annual FY2025 reading of $812.8 million, up 13.8% over the prior year.
  • Current Assets was $812.8 million for Q4 2025 at Recursion Pharmaceuticals, up from $714.1 million in the prior quarter.
  • Across five years, Current Assets topped out at $812.8 million in Q4 2025 and bottomed at $221.8 million in Q1 2021.
  • Average Current Assets over 5 years is $537.3 million, with a median of $540.4 million recorded in 2021.
  • The sharpest move saw Current Assets surged 179.26% in 2022, then plummeted 30.18% in 2024.
  • Year by year, Current Assets stood at $534.7 million in 2021, then increased by 6.56% to $569.8 million in 2022, then fell by 23.11% to $438.1 million in 2023, then soared by 63.02% to $714.3 million in 2024, then grew by 13.8% to $812.8 million in 2025.
  • Business Quant data shows Current Assets for RXRX at $812.8 million in Q4 2025, $714.1 million in Q3 2025, and $587.2 million in Q2 2025.